Cargando…

Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report

Pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor that has been approved for treatment of a wide variety of malignancies including non-small-cell lung cancer (NSCLC). Immune-mediated colitis is a known adverse effect of pembrolizumab which can lead to the treatment interruption, althou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damato, Angela, De Marco, Loredana, Serra, Silvia, Larocca, Mario, Arias, Alicia Garcia, Rondini, Ermanno, Pinto, Carmine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248363/ https://www.ncbi.nlm.nih.gov/pubmed/34221986 http://dx.doi.org/10.3389/fonc.2021.670415

Ejemplares similares

Severe Rhabdomyolysis during Treatment with Trabectedin in Combination with a Herbal Drug in a Patient with Metastatic Synovial Sarcoma: A Case Report
por: Damato, Angela, et al.
Publicado: (2017)

Pembrolizumab: Autoimmune haemolytic anaemia and immune-mediated colitis: case report
Publicado: (2021)

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
por: Krukowska, Kinga, et al.
Publicado: (2020)

SAT-661 The Lesser Evil: Pembrolizumab Induced Remission of Metastatic Melanoma with Autoimmune Diabetes, Hypothyroidism, and Colitis
por: Harris, Asaf, et al.
Publicado: (2020)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab
por: Moliner, Laura, et al.
Publicado: (2020)

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
por: Tsai, Jeng-Shiuan, et al.
Publicado: (2022)

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
por: Cui, Pengfei, et al.
Publicado: (2020)

Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC
por: Roborel de Climens, Ferréol, et al.
Publicado: (2021)

An autopsy case of autoimmune meningoencephalitis caused by pembrolizumab
por: Hiraoka, Yuhi, et al.
Publicado: (2022)

Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report
por: Tanaka, Takeshi, et al.
Publicado: (2022)

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
por: Ito, Katsuhiro, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Rapid Onset of Takotsubo Cardiomyopathy Induced by an Infusion Reaction to Pembrolizumab in a Patient with NSCLC
por: Okamatsu, Yuki, et al.
Publicado: (2020)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Fujimoto, Daichi, et al.
Publicado: (2021)

Prolongation of Pregnancy by Rest in the Last Month
Publicado: (1914)

Multiple Autoimmune Complications After a Single Dose of Pembrolizumab
por: Ahdi, Hardeep S, et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
por: Qu, Jialin, et al.
Publicado: (2020)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
por: van der Woude, Lieke L, et al.
Publicado: (2022)

Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma
por: Yamanaka, Yumie, et al.
Publicado: (2019)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Case Report: Prolonged remission of metastatic cisplatin-refractory nasopharyngeal carcinoma with Pembrolizumab
por: Wang, Wei Cen, et al.
Publicado: (2023)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
por: Shaverdian, Narek, et al.
Publicado: (2021)

Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab
por: Zibelman, Matthew, et al.
Publicado: (2016)

Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
por: Cheema, Anmol, et al.
Publicado: (2018)

A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab
por: Arora, Aakriti, et al.
Publicado: (2020)

Autoimmune diabetes from pembrolizumab: A case report and review of literature
por: Bhanderi, Hardikkumar, et al.
Publicado: (2023)

Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report
por: Miranda Baleiras, Mafalda, et al.
Publicado: (2022)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma
por: Saint, Angélique, et al.
Publicado: (2020)

Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection
por: Zhou, Cheng, et al.
Publicado: (2019)

Late‐onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer
por: Ichihara, Seiya, et al.
Publicado: (2022)

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
por: Damato, Angela, et al.
Publicado: (2021)

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
por: Beck, Kristen M., et al.
Publicado: (2016)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
por: Wan, Ning, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8t1ttgsvlk9bsno8hbpn19kd6a